AFP and lung carcinoma: For example, altered glycosylation could be presented in the early stages of lung cancer [39], where some of the glycosylation changes (highly sialylated, branched and outer arm fucosylated glycans) were detectable as early as in stage I. Monitoring core-fucosylation levels in alpha-fetoprotein is a sensitive marker for early tumour detection [40].